EP1080113A4 - Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases - Google Patents

Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases

Info

Publication number
EP1080113A4
EP1080113A4 EP99924253A EP99924253A EP1080113A4 EP 1080113 A4 EP1080113 A4 EP 1080113A4 EP 99924253 A EP99924253 A EP 99924253A EP 99924253 A EP99924253 A EP 99924253A EP 1080113 A4 EP1080113 A4 EP 1080113A4
Authority
EP
European Patent Office
Prior art keywords
inhibitors
radiation
treatment
growth factor
factor receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99924253A
Other languages
German (de)
French (fr)
Other versions
EP1080113A1 (en
Inventor
Harlan W Waksal
Mansoor N Saleh
Francisco Robert
Donald Jay Buchsbaum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UAB Research Foundation
ImClone LLC
Original Assignee
UAB Research Foundation
ImClone Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UAB Research Foundation, ImClone Systems Inc filed Critical UAB Research Foundation
Publication of EP1080113A1 publication Critical patent/EP1080113A1/en
Publication of EP1080113A4 publication Critical patent/EP1080113A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
EP99924253A 1998-05-15 1999-05-14 Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases Withdrawn EP1080113A4 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US79612 1987-07-30
US8561398P 1998-05-15 1998-05-15
US7961298A 1998-05-15 1998-05-15
US85613P 1998-05-15
US20613898A 1998-12-07 1998-12-07
US206138 1998-12-07
PCT/US1999/010741 WO1999060023A1 (en) 1998-05-15 1999-05-14 Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases

Publications (2)

Publication Number Publication Date
EP1080113A1 EP1080113A1 (en) 2001-03-07
EP1080113A4 true EP1080113A4 (en) 2002-04-17

Family

ID=27373511

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99924253A Withdrawn EP1080113A4 (en) 1998-05-15 1999-05-14 Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases

Country Status (14)

Country Link
EP (1) EP1080113A4 (en)
JP (1) JP2002515511A (en)
KR (1) KR20010071271A (en)
CN (1) CN1314917A (en)
AU (1) AU4079999A (en)
BR (1) BR9910511A (en)
CA (1) CA2332331A1 (en)
CZ (1) CZ20004224A3 (en)
HK (1) HK1040720A1 (en)
IL (1) IL139707A0 (en)
MX (1) MXPA00011248A (en)
PL (1) PL348634A1 (en)
SK (1) SK17282000A3 (en)
WO (1) WO1999060023A1 (en)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
LU91067I2 (en) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab and its variants and immunochemical derivatives including immotoxins
EP1745799B1 (en) 1998-03-04 2015-09-02 The Trustees of The University of Pennsylvania Compositions and methods of treating tumors
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
WO2000074634A2 (en) 1999-06-03 2000-12-14 Au Jessie L S Methods and compositions for modulating cell proliferation and cell death
GB9925958D0 (en) * 1999-11-02 1999-12-29 Bundred Nigel J Therapeutic use
UA74803C2 (en) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. A stable polymorph of n-(3-ethynylphenyl)-6,7-bis(2-methoxyetoxy)-4-quinazolinamine hydrochloride, a method for producing thereof (variants) and pharmaceutical use
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
AU9500201A (en) * 2000-08-09 2002-02-18 Imclone Systems Inc Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
WO2002045653A2 (en) * 2000-12-08 2002-06-13 Uab Research Foundation Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody
CU22979A1 (en) * 2000-12-08 2004-09-09 Centro Inmunologia Molecular IMMUNOTHERAPEUTIC COMBINATION FOR THE TREATMENT OF TUMORS OVER-EXPRESSING RECEPTORS WITH KINASE ACTIVITY IN TYPOSINE WASTE
US7081454B2 (en) 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
JP2005526506A (en) 2002-03-04 2005-09-08 イムクローン システムズ インコーポレイティド KDR specific human antibody and use thereof
ES2299692T3 (en) * 2002-04-02 2008-06-01 Nerviano Medical Sciences S.R.L. COMBINED THERAPY AGAINST TUMORS THAT INCLUDE DERIVATIVES OF REPLACED ACRILOIL DISTMYCIN AND RADIOTHERAPY.
EP2316922B1 (en) 2002-05-24 2013-05-22 Merck Sharp & Dohme Corp. Neutralizing human anti-IGFR antibody
CA2524305C (en) 2003-05-01 2015-12-08 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
CN1972712A (en) 2003-06-09 2007-05-30 塞缪尔·瓦克萨尔 Method of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular agonist
US7312215B2 (en) 2003-07-29 2007-12-25 Bristol-Myers Squibb Company Benzimidazole C-2 heterocycles as kinase inhibitors
RS20060099A (en) 2003-08-13 2008-08-07 Pfizer Products Inc., Modified human igf-1r antibodies
JP2007510434A (en) 2003-11-12 2007-04-26 シェーリング　コーポレイション A plasmid system for multigene expression.
AR046639A1 (en) 2003-11-21 2005-12-14 Schering Corp ANTI-IGFR1 ANTIBODY THERAPEUTIC COMBINATIONS
JP4734319B2 (en) 2004-03-19 2011-07-27 イムクローン・リミテッド・ライアビリティ・カンパニー Human anti-epidermal growth factor receptor antibody
JP2008501654A (en) 2004-06-03 2008-01-24 エフ．ホフマン−ラ　ロシュ　アーゲー Treatment with cisplatin and EGFR inhibitor
DE602005025685D1 (en) 2004-12-03 2011-02-10 Schering Corp BIOLOGICAL MARKERS FOR THE PRESELECTION OF PATIENTS FOR ANTI-IGF1R THERAPY
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
KR101246504B1 (en) 2005-06-17 2013-03-26 임클론 엘엘씨 Anti-PDGFRalpha Antibodies
JP5055284B2 (en) 2005-09-20 2012-10-24 オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー Biological markers for predicting anti-cancer responses to insulin-like growth factor-1 receptor kinase inhibitors
EP1940881B1 (en) * 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
PL2056874T3 (en) 2006-08-21 2013-02-28 Hoffmann La Roche Tumor therapy with an anti-vegf antibody
PT2129396E (en) 2007-02-16 2013-11-18 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
WO2008119566A2 (en) * 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific bispecific binders
CN101821292B (en) 2007-09-05 2014-03-26 霍夫曼-拉罗奇有限公司 Combination therapy with type I and type II anti-cd20 antibodies
US20090098118A1 (en) 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
AR071891A1 (en) 2008-05-30 2010-07-21 Imclone Llc ANTI-FLT3 HUMAN ANTIBODIES (THIROSINE KINASE 3 RECEPTOR HUMAN FMS TYPE)
UA104868C2 (en) 2008-08-15 2014-03-25 Меррімак Фармасьютікалз, Інк. Method for treating patient having neoplastic tumor according to predicted reaction
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
JP2012519170A (en) 2009-02-26 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー INSITU method for monitoring EMT status of tumor cells in vivo
WO2010107968A1 (en) 2009-03-18 2010-09-23 Osi Pharmaceuticals, Inc. Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor
US20120121596A1 (en) 2009-03-20 2012-05-17 Germaine Fuh Bispecific anti-her antibodies
EP2236139A1 (en) 2009-03-31 2010-10-06 F. Hoffmann-La Roche AG Combination therapy of erlotinib with an anti-IGF-1R antibody, which does not inhibit binding of insulin to the insulin receptor
US20100247484A1 (en) 2009-03-31 2010-09-30 Heinrich Barchet Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3
CA2769595A1 (en) 2009-08-14 2011-02-17 Roche Glycart Ag Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantrone
TWI409079B (en) 2009-08-14 2013-09-21 Roche Glycart Ag Combination therapy of an afucosylated cd20 antibody with bendamustine
AR078161A1 (en) 2009-09-11 2011-10-19 Hoffmann La Roche VERY CONCENTRATED PHARMACEUTICAL FORMULATIONS OF AN ANTIBODY ANTI CD20. USE OF THE FORMULATION. TREATMENT METHOD
AU2011223643A1 (en) 2010-03-03 2012-06-28 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2011109584A2 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP2859893A1 (en) 2010-03-11 2015-04-15 Merrimack Pharmaceuticals, Inc. Use of ERBB3 inhibitors in the treatment of triple negative and basal-like breast cancers
MX342590B (en) 2010-04-27 2016-10-05 Roche Glycart Ag Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor.
TW201208703A (en) 2010-08-17 2012-03-01 Roche Glycart Ag Combination therapy of an afucosylated CD20 antibody with an anti-VEGF antibody
TW201302793A (en) 2010-09-03 2013-01-16 Glaxo Group Ltd Novel antigen binding proteins
KR20130088170A (en) 2010-12-16 2013-08-07 로슈 글리카트 아게 Combination therapy of an afucosylated cd20 antibody with a mdm2 inhibitor
AU2012212075A1 (en) 2011-02-02 2013-07-18 Amgen Inc. Methods and compositons relating to inhibition of IGF-1R
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy
JP5908972B2 (en) 2011-04-07 2016-04-26 アムジエン・インコーポレーテツド Novel antigen binding protein
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
EP2776042B1 (en) 2011-11-11 2019-03-20 Duke University Combination drug therapy for the treatment of solid tumors
US20130302274A1 (en) 2011-11-25 2013-11-14 Roche Glycart Ag Combination therapy
ES2842201T3 (en) * 2012-02-23 2021-07-13 Daiichi Sankyo Europe Gmbh HER3 inhibitor for radiosensitivity modulation
AR090263A1 (en) 2012-03-08 2014-10-29 Hoffmann La Roche COMBINED ANTIBODY THERAPY AGAINST HUMAN CSF-1R AND USES OF THE SAME
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
CN111437386A (en) 2012-09-07 2020-07-24 吉宁特有限公司 Combination therapy of type II anti-CD 20 antibodies with selective Bcl-2 inhibitors
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
WO2015100459A2 (en) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
MX2016012285A (en) 2014-03-24 2017-01-23 Genentech Inc Cancer treatment with c-met antagonists and correlation of the latter with hgf expression.
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
CN113607945A (en) 2015-07-07 2021-11-05 豪夫迈·罗氏有限公司 Combination therapy of an anti-HER 2 antibody-drug conjugate and a Bcl-2 inhibitor
KR20180100125A (en) 2015-12-03 2018-09-07 아지오스 파마슈티컬스 아이엔씨. MAT2A inhibitor for treating MTAP null cancer
US20190015393A1 (en) 2016-01-18 2019-01-17 Institut National De La Santé Et De La Recherche Médicale (Inserm) The use of a temporary inhibitor of p53 for preventing or reducing cancer relapse
WO2017205465A2 (en) 2016-05-24 2017-11-30 Griswold Karl Edwin Antibodies and methods of making same
EP3658188A1 (en) 2017-07-26 2020-06-03 H. Hoffnabb-La Roche Ag Combination therapy with a bet inhibitor and a bcl-2 inhibitor
EP3658584A1 (en) 2017-07-26 2020-06-03 H. Hoffnabb-La Roche Ag Combination therapy with a bet inhibitor, a bcl-2 inhibitor and an anti-cd20 antibody
EP3688034A4 (en) * 2017-09-29 2021-06-23 Wuxi Biologics Ireland Limited. Bispecific antibodies against EGFR and PD-1
TW202011946A (en) 2018-04-18 2020-04-01 瑞士商赫孚孟拉羅股份公司 Combination therapy with a bet inhibitor and a proteasome inhibitor
WO2020234445A1 (en) 2019-05-23 2020-11-26 F. Hoffmann-La Roche Ag Combination therapy with a bet inhibitor and a bcl-2 inhibitor
WO2021155006A1 (en) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibitors of cyclin-dependent kinases and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040210A1 (en) * 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040210A1 (en) * 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BALABAN NAOMI ET AL: "The effect of ionizing radiation on signal transduction: Antibodies to EGF receptor sensitize A431 cells to radiation.", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1314, no. 1-2, 1996, pages 147 - 156, XP001055207, ISSN: 0006-3002 *
GOLDKORN T ET AL: "EGF receptor phosphorylation is affected by ionizing radiation", BIOCHIMICA ET BIOPHYSICA ACTA. MOLECULAR CELL RESEARCH, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 1358, no. 3, 11 October 1997 (1997-10-11), pages 289 - 299, XP004277704, ISSN: 0167-4889 *
SALEH M ET AL: "In vitro and in vivo evaluation of the cytotoxicity of radiation combined with chimeric monoclonal antibody to the epidermal growth factor receptor.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 37, 1996, 87th Annual Meeting of the American Association for Cancer Research;Washington, D.C., USA; April 20-24, 1996, 1996, pages 612, XP001027768, ISSN: 0197-016X *
SALEH MANSOOR N ET AL: "Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation.", CANCER BIOTHERAPY & RADIOPHARMACEUTICALS, vol. 14, no. 6, 1999, pages 451 - 463, XP001027767, ISSN: 1084-9785 *
See also references of WO9960023A1 *

Also Published As

Publication number Publication date
HK1040720A1 (en) 2002-06-21
SK17282000A3 (en) 2002-04-04
CN1314917A (en) 2001-09-26
AU4079999A (en) 1999-12-06
KR20010071271A (en) 2001-07-28
IL139707A0 (en) 2002-02-10
BR9910511A (en) 2001-11-20
PL348634A1 (en) 2002-06-03
MXPA00011248A (en) 2004-09-06
CA2332331A1 (en) 1999-11-25
JP2002515511A (en) 2002-05-28
WO1999060023A1 (en) 1999-11-25
CZ20004224A3 (en) 2002-02-13
EP1080113A1 (en) 2001-03-07

Similar Documents

Publication Publication Date Title
IL139707A0 (en) Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
HUP0201480A2 (en) Treatment of refractory human tumors with epidermal growth factor receptor antagonists
HK1026209A1 (en) Substituted quinazoline derivatives and their use as tyrosine kinase inhibitors
HUP9904361A3 (en) Use of isobutylgaba and its derivatives for the treatment of pain
MD960217A (en) Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
GB9903841D0 (en) Diagnosis and treatment of cancer
EP1073496A4 (en) Improved irradiation catheter and method of use
AU2002351397A1 (en) Systems and methods using vasoconstriction for improved thermal treatment of tissues
IL126768A0 (en) Use of protein kinase c inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
EP1097165A4 (en) Novel inhibitors of angiogenesis and tumor growth
AU6528800A (en) Methods and apparatuses for radiation treatment
HK1025327A1 (en) Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of begnin prostatic hyperplasia
EP1169319A4 (en) Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases
HK1043113A1 (en) Telomerase inhibitors and methods of their use
DE60030164D1 (en) 3-HETEROARYLIDENYL-2-INDOLINONE DERIVATIVES WITH PROTEIN OF KINASE MODULATING ACTIVITY AND FOR USE IN CANCER THERAPY
HUP0104374A3 (en) Growth hormone releasing compounds and their antagonists for use for treatment of tumors
EP1054979A4 (en) Compositions and methods for sensitizing and inhibiting growth of human tumor cells
GB9811598D0 (en) Diagnosis and treatment of cancer
HK1046915A1 (en) Catalytic domains of the human hepatocyte growth factor receptor tyrosine kinase and methods for identification of inhibitors thereof
EP1181374A4 (en) Novel murine and human kinases
IL153769A0 (en) Methods of treating cancer and the pain associated therewith using endothelin antagonists
NO20021430L (en) Procedure for Therapeutic Management of Extrauterine Proliferation of Endometrial Tissue, Chronic Pelvic Pain and Ovary Obstruction
IL132531A0 (en) Detection and therapy of tumors
EP1210370A4 (en) Human tumor necrosis factor receptor tr16
IL141355A0 (en) Tpl-2/cot kinase and methods of use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001215

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BUCHSBAUM, DONALD, JAY

Inventor name: ROBERT, FRANCISCO

Inventor name: SALEH, MANSOOR, N.

Inventor name: WAKSAL, HARLAN, W.

A4 Supplementary search report drawn up and despatched

Effective date: 20020301

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07K 16/00 A, 7A 61K 39/395 B, 7A 61N 5/10 B, 7C 07K 16/28 B

TPAD Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOS TIPA

17Q First examination report despatched

Effective date: 20030114

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050531